Keywords: antisoma/novartis, conduct, second, ph, iii, asa404, trial
Antisoma/Novartis to conduct second Ph III ASA404 trial this year
Article | 04 August 2008
London, UK-headquartered cancer drug developer Antisoma says its tumour-vascular disrupting agent, ASA404, will enter a second Phase III trial this ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
